Development and Validation of a UV Spectroscopic Method to Estimate Eltrombopag Olamine along with Bulk and In-house Formulation

Author:

Aabid Mohammed1,Memon Shakeel1,Pathan Dilnawaz2,Hangad Tabbussum1

Affiliation:

1. Department of Quality Assurance, M. C. E. Society’s Allana College of Pharmacy, Azam Campus, Camp, Pune.

2. HOD, Department of Pharmaceutics, Trinity College of Pharmacy, Pune.

Abstract

The current UV Spectroscopic method developed involving ethanol as a solvent is simple, fast, specific, precise, and sensitive for the estimation of Eltrombopag Olamine in bulk in day-to-day analysis. As per the ICH Q2 (R1) guideline, the method was validated. Eltrombopag Olamine is a drug used to treat thrombocytopenia (a low blood platelet count) in adults and youngsters with chronic immune idiopathic thrombocytopenic purpura that didn't get well with different treatments. Eltrombopag Olamine is additionally accustomed to treating severe aplastic anemia. It’s conjointly being studied within the treatment of different conditions and kinds of cancer. Eltrombopag Olamine binds to the thrombopoietin receptor, which causes the bone marrow to create more platelets. It’s class of thrombopoietin receptor agonists, also known as Promacta. Eltrombopag is also recently approved (2012) for the treatment of thrombocytopenia in a patient with chronic hepatitis C to start and sustain interferon-based therapy. The solvent used in the entire method development and validation was ethanol. The maximum wavelength of absorption was found to be 423nm. Beer’s law was obeyed in the concentration range of 5 to 30ug/ml with a correlation coefficient of 0.9966. The method was precise with an RSD of less than 2%, the LOD, and LOQ were found to be 6.18ug/ml and 18.7ug/ml respectively, % recovery of the drug is 98 to 100%. The method was validated for linearity, precision, accuracy, and robustness and all parameters were found to be satisfactory which proves that this method can be used for routine analysis of Eltrombopag Olamine.

Publisher

A and V Publications

Reference20 articles.

1. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/eltrombopag-olamine.

2. https://pubchem.ncbi.nlm.nih.gov/compound/Eltrombopag-olamine.

3. https://www.drugbank.ca/drugs/DB12935accessedin August2019.

4. ICH Guideline Q2 (R1), Validation of Analytical Procedures, Methodology, 1996.

5. Zhang, Y, Kolesar, J M. Eltrombopag: An Oral Thrombopoietin Receptor Agonist for the Treatment of Idiopathic Thrombocytopenic Purpura. Clinical Therapeutics. 2011; 33(11): 1560-1576. doi:10.1016/j.clinthera.2011.10.004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3